Key facts
- The Trump administration is launching a diplomatic effort in Europe.
- The initiative aims to persuade European governments to increase their spending on medicines.
- The goal is to follow Britain's lead in medicine spending.
- U.S. embassies are conveying that American patients overpay for medicines.
- Industry figures warn the EU risks losing pharmaceutical investment.
The Trump administration is launching a broad diplomatic effort across Europe, urging governments to increase their spending on medicines. U.S. embassies are tasked with conveying the message that American patients are overpaying and that European nations should contribute more. Industry sources suggest that failure to comply could result in the European Union losing out on pharmaceutical investment, following the model set by Britain's approach to medicine spending.